11 results on '"Simone, Nicole L."'
Search Results
2. The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster
- Author
-
Jin, Lianjin, Lim, Meng, Zhao, Shuping, Sano, Yuri, Simone, Brittany A., Savage, Jason E., Wickstrom, Eric, Camphausen, Kevin, Pestell, Richard G., and Simone, Nicole L.
- Published
- 2014
- Full Text
- View/download PDF
3. Twenty-five year results of the national cancer institute randomized breast conservation trial
- Author
-
Simone, Nicole L., Dan, Tu, Shih, Joanna, Smith, Sharon L., Sciuto, Linda, Lita, Elena, Lippman, Marc E., Glatstein, Eli, Swain, Sandra M., Danforth, David N., and Camphausen, Kevin
- Published
- 2012
- Full Text
- View/download PDF
4. microRNA's: The short link between cancer and RT induced DNA damage response.
- Author
-
Wright, Chris, Tu Dan, Dicker, Adam P., and Simone, Nicole L.
- Subjects
MICRORNA ,DNA damage ,RADIOTHERAPY - Abstract
A preview of the article "microRNA's: The short link between cancer and RT induced DNA damage response" by Chris Wright et al., which appeared in the periodical "Frontiers in Oncology" on May 20, 2014, is presented.
- Published
- 2014
- Full Text
- View/download PDF
5. Chronoradiobiology of Breast Cancer: The Time Is Now to Link Circadian Rhythm and Radiation Biology.
- Author
-
Nelson, Nicolas, Lombardo, Joseph, Matlack, Lauren, Smith, Alexandria, Hines, Kamryn, Shi, Wenyin, and Simone, Nicole L.
- Subjects
RADIOBIOLOGY ,CIRCADIAN rhythms ,BREAST cancer ,ETIOLOGY of cancer ,THERAPEUTICS ,DNA damage ,CLOCK genes - Abstract
Circadian disruption has been linked to cancer development, progression, and radiation response. Clinical evidence to date shows that circadian genetic variation and time of treatment affect radiation response and toxicity for women with breast cancer. At the molecular level, there is interplay between circadian clock regulators such as PER1, which mediates ATM and p53-mediated cell cycle gating and apoptosis. These molecular alterations may govern aggressive cancer phenotypes, outcomes, and radiation response. Exploiting the various circadian clock mechanisms may enhance the therapeutic index of radiation by decreasing toxicity, increasing disease control, and improving outcomes. We will review the body's natural circadian rhythms and clock gene-regulation while exploring preclinical and clinical evidence that implicates chronobiological disruptions in the etiology of breast cancer. We will discuss radiobiological principles and the circadian regulation of DNA damage responses. Lastly, we will present potential rational therapeutic approaches that target circadian pathways to improve outcomes in breast cancer. Understanding the implications of optimal timing in cancer treatment and exploring ways to entrain circadian biology with light, diet, and chronobiological agents like melatonin may provide an avenue for enhancing the therapeutic index of radiotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Personalized Nutrition as a Key Contributor to Improving Radiation Response in Breast Cancer.
- Author
-
Shastri, Anuradha A., Lombardo, Joseph, Okere, Samantha C., Higgins, Stephanie, Smith, Brittany C., DeAngelis, Tiziana, Palagani, Ajay, Hines, Kamryn, Monti, Daniel A., Volpe, Stella, Mitchell, Edith P., and Simone, Nicole L.
- Subjects
BREAST cancer ,DEFICIENCY diseases ,CANCER patients ,RADIATION ,METABOLIC regulation - Abstract
Understanding metabolic and immune regulation inherent to patient populations is key to improving the radiation response for our patients. To date, radiation therapy regimens are prescribed based on tumor type and stage. Patient populations who are noted to have a poor response to radiation such as those of African American descent, those who have obesity or metabolic syndrome, or senior adult oncology patients, should be considered for concurrent therapies with radiation that will improve response. Here, we explore these populations of breast cancer patients, who frequently display radiation resistance and increased mortality rates, and identify the molecular underpinnings that are, in part, responsible for the radiation response and that result in an immune-suppressive tumor microenvironment. The resulting immune phenotype is discussed to understand how antitumor immunity could be improved. Correcting nutrient deficiencies observed in these populations should be considered as a means to improve the therapeutic index of radiation therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Loratadine dysregulates cell cycle progression and enhances the effect of radiation in human tumor cell lines.
- Author
-
Soule, Benjamin P., Simone, Nicole L., DeGraff, William G., Choudhuri, Rajani, Cook, John A., and Mitchell, James B.
- Subjects
- *
LORATADINE , *CELL cycle , *TUMOR treatment , *RADIATION , *HISTAMINE , *CELL lines - Abstract
Background: The histamine receptor-1 (H1)-antagonist, loratadine has been shown to inhibit growth of human colon cancer xenografts in part due to cell cycle arrest in G2/M. Since this is a radiation sensitive phase of the cell cycle, we sought to determine if loratadine modifies radiosensitivity in several human tumor cell lines with emphasis on human colon carcinoma (HT29). Methods: Cells were treated with several doses of loratadine at several time points before and after exposure to radiation. Radiation dose modifying factors (DMF) were determined using full radiation dose response survival curves. Cell cycle phase was determined by flow cytometry and the expression of the cell cycle-associated proteins Chk1, pChk1ser345, and Cyclin B was analyzed by western blot. Results: Loratadine pre-treatment of exponentially growing cells (75 μM, 24 hours) increased radiation-induced cytotoxicity yielding a radiation DMF of 1.95. However, treatment of plateau phase cells also yielded a DMF of 1.3 suggesting that mechanisms other than cell cycle arrest also contribute to loratadine-mediated radiation modification. Like irradiation, loratadine initially induced G2/M arrest and activation of the cell-cycle associated protein Chk1 to pChk1ser345, however a subsequent decrease in expression of total Chk1 and Cyclin B correlated with abrogation of the G2/M checkpoint. Analysis of DNA repair enzyme expression and DNA fragmentation revealed a distinct pattern of DNA damage in loratadine-treated cells in addition to enhanced radiation-induced damage. Taken together, these data suggest that the observed effects of loratadine are multifactorial in that loratadine 1) directly damages DNA, 2) activates Chk1 thereby promoting G2/M arrest making cells more susceptible to radiation-induced DNA damage and, 3) downregulates total Chk1 and Cyclin B abrogating the radiation-induced G2/M checkpoint and allowing cells to re-enter the cell cycle despite the persistence of damaged DNA. Conclusions: Given this unique possible mechanism of action, loratadine has potential as a chemotherapeutic agent and as a modifier of radiation responsiveness in the treatment of cancer and, as such, may warrant further clinical evaluation. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
8. Ionizing Radiation-Induced Oxidative Stress Alters miRNA Expression.
- Author
-
Simone, Nicole L., Soule, Benjamin P., Ly, David, Saleh, Anthony D., Savage, Jason E., DeGraff, William, Cook, John, Harris, Curtis C., Gius, David, and Mitchell, James B.
- Subjects
- *
RNA , *NUCLEIC acids , *PROTEINS , *RIBOSE , *RADIATION , *ETOPOSIDE , *HYDROGEN peroxide , *GENETIC toxicology , *CYSTEINE proteinases - Abstract
Background: MicroRNAs (miRNAs) are small, highly conserved, non-coding RNA that alter protein expression and regulate multiple intracellular processes, including those involved in the response to cellular stress. Alterations in miRNA expression may occur following exposure to several stress-inducing anticancer agents including ionizing radiation, etoposide, and hydrogen peroxide (H2O2). Methodology/Principal Findings: Normal human fibroblasts were exposed to radiation, H2O2, or etoposide at doses determined by clonogenic cell survival curves. Total RNA was extracted and miRNA expression was determined by microarray. Time course and radiation dose responses were determined using RT-PCR for individual miRNA species. Changes in miRNA expression were observed for 17 miRNA species following exposure to radiation, 23 after H2O2 treatment, and 45 after etoposide treatment. Substantial overlap between the miRNA expression changes between agents was observed suggesting a signature miRNA response to cell stress. Changes in the expression of selected miRNA species varied in response to radiation dose and time. Finally, production of reactive oxygen species (ROS) increased with increasing doses of radiation and pre-treatment with the thiol antioxidant cysteine decreased both ROS production and the miRNA response to radiation. Conclusions: These results demonstrate a common miRNA expression signature in response to exogenous genotoxic agents including radiation, H2O2, and etoposide. Additionally, pre-treatment with cysteine prevented radiation-induced alterations in miRNA expression which suggests that miRNAs are responsive to oxidative stress. Taken together, these results imply that miRNAs play a role in cellular defense against exogenous stress and are involved in the generalized cellular response to genotoxic oxidative stress. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
9. Is Host Metabolism the Missing Link to Improving Cancer Outcomes?
- Author
-
Wright, Christopher M., Shastri, Anuradha A., Bongiorno, Emily, Palagani, Ajay, Rodeck, Ulrich, and Simone, Nicole L.
- Subjects
TUMOR surgery ,OBESITY complications ,BASAL metabolism ,CANCER patients ,DIET ,HEALTH behavior ,IMMUNE system ,INFLAMMATION ,ONCOLOGISTS ,TUMORS ,METABOLIC syndrome ,TREATMENT effectiveness ,PATIENT-centered care ,DISEASE progression ,INDIVIDUALIZED medicine ,DISEASE complications - Abstract
For the past 100 years, oncologists have relentlessly pursued the destruction of tumor cells by surgical, chemotherapeutic or radiation oncological means. Consistent with this focus, treatment plans are typically based on key characteristics of the tumor itself such as disease site, histology and staging based on local, regional and systemic dissemination. Precision medicine is similarly built on the premise that detailed knowledge of molecular alterations of tumor cells themselves enables better and more effective tumor cell destruction. Recently, host factors within the tumor microenvironment including the vasculature and immune systems have been recognized as modifiers of disease progression and are being targeted for therapeutic gain. In this review, we argue that—to optimize the impact of old and new treatment options—we need to take account of an epidemic that occurs independently of—but has major impact on—the development and treatment of malignant diseases. This is the rapidly increasing number of patients with excess weight and its' attendant metabolic consequences, commonly described as metabolic syndrome. It is well established that patients with altered metabolism manifesting as obesity, metabolic syndrome and chronic inflammation have an increased incidence of cancer. Here, we focus on evidence that these patients also respond differently to cancer therapy including radiation and provide a perspective how exercise, diet or pharmacological agents may be harnessed to improve therapeutic responses in this patient population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. The chemistry and biology of nitroxide compounds
- Author
-
Soule, Benjamin P., Hyodo, Fuminori, Matsumoto, Ken-ichiro, Simone, Nicole L., Cook, John A., Krishna, Murali C., and Mitchell, James B.
- Subjects
- *
NITROGEN oxides , *BLOOD circulation disorders , *MAGNETIC resonance imaging , *FREE radical reactions - Abstract
Abstract: Cyclic nitroxides are a diverse group of stable free radicals that have unique antioxidant properties. Because of their ability to interact with free radicals, they have been used for many years as biophysical tools. During the past 15–20 years, however, many interesting biochemical interactions have been discovered and harnessed for therapeutic applications. Biologically relevant effects of nitroxides have been described, including their ability to degrade superoxide and peroxide, inhibit Fenton reactions, and undergo radical–radical recombination. Cellular studies defined the activity of nitroxides in vitro. By modifying oxidative stress and altering the redox status of tissues, nitroxides have been found to interact with and alter many metabolic processes. These interactions can be exploited for therapeutic and research use, including protection against ionizing radiation, as probes in functional magnetic resonance imaging, cancer prevention and treatment, control of hypertension and weight, and protection from damage resulting from ischemia/reperfusion injury. Although much remains to be done, many applications have been well studied and some are currently being tested in clinical trials. The therapeutic and research uses of nitroxide compounds are reviewed here with a focus on the progress from initial development to modern trials. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
11. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study
- Author
-
Singh, Anurag K., Ménard, Cynthia, Guion, Peter, Simone, Nicole L., Smith, Sharon, Crouse, Nancy Sears, Godette, Denise J., Cooley-Zgela, Theresa, Sciuto, Linda C., Coleman, Jonathan, Pinto, Peter, Albert, Paul S., Camphausen, Kevin, and Coleman, C. Norman
- Subjects
- *
CANCER education , *MALE reproductive organs , *RADIOTHERAPY , *ONCOLOGY - Abstract
Purpose: Our goal was to test the ability of intrarectal amifostine to limit symptoms of radiation proctitis. Methods and Materials: The first 18 patients received 1 g of intrarectal amifostine suspension placed 30–45 min before each radiation treatment. The following 12 patients received 2 g of amifostine. Total dose prescribed ranged from 66 to 76 Gy. All patients were treated with three-dimensional conformal radiation therapy. The suspension remained intrarectal during treatment and was expelled after treatment. For gastrointestinal symptoms, during treatment and follow-up, all patients had a Radiation Therapy Oncology Group (RTOG) grade recorded. Results: Median follow-up was 18 months (range, 6–24 months). With 2 g vs. 1 g amifostine, there was a nearly significant decrease in RTOG Grade 2 acute rectal toxicity. Seven weeks after the start of radiation therapy, the incidence of Grade 2 toxicity was 33% in the 1-g group (6/18) compared with 0% (0/12) in the 2-g group (p = 0.06). No Grade 3 toxicity or greater occurred in this study. Conclusion: This trial suggests greater rectal radioprotection from acute effects with 2 g vs. 1 g amifostine suspension. Further studies should be conducted in populations at higher risk for developing symptomatic acute and late proctitis. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.